<DOC>
	<DOCNO>NCT01022996</DOCNO>
	<brief_summary>This study assess RAD001 patient refractory relapse Hodgkin Lymphoma progress high-dose chemotherapy Autologous Stem cell transplant and/or gemcitabine- vinorelbine- vinblastine-based treatment .</brief_summary>
	<brief_title>Study RAD001 Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy Autologous Stem Cell Transplant and/or After Gemcitabine- Vinorelbine- Vinblastine-based Treatment .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Patients history classical Hodgkin 's lymphoma progress highdose chemotherapy Autologous Stem cell transplant and/or gemcitabine vinorelbine vinblastinebased treatment Patients least one site measurable disease measure ≥ 2.0cm confirm PET CT Scan ( MRI ) Patients adequate bone marrow , liver renal function ( confirmed laboratory value ) Patients fast serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fast triglyceride ≤ 2.5 x ULN Previous treatment mTOR inhibitor Prior allogeneic stem cell transplant Chemotherapy , monoclonal antibody therapy , major surgery treatment investigational drug within 4 week start study treatment Another malignancy within 3 year study entry ( except adequately treat nonmelanoma skin cancer carcinoma situ cervix ) Severe and/or uncontrolled medical condition could affect participation study Female patient pregnant breastfeeding ; patient willing use adequate birth control study 8 week last study treatment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Hodgkin Disease</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Neoplasms Histological type</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Hemic Lymphatic Diseases</keyword>
	<keyword>Recurrent Lymphoma</keyword>
	<keyword>Refractory Lymphoma</keyword>
	<keyword>Relapsed Lymphoma</keyword>
	<keyword>Classical Hodgkin Lymphoma</keyword>
	<keyword>Classical Hodgkin 's Disease</keyword>
	<keyword>Nodular sclerosing Hodgkin Lymphoma</keyword>
	<keyword>Mixed-cellularity Hodgkin Lymphoma</keyword>
	<keyword>Lymphocyte-rich Hodgkin Lymphoma</keyword>
	<keyword>Lymphocyte deplete Hodgkin Lymphoma</keyword>
</DOC>